Scios Inc

SuperGen, Inc., a pharmaceutical company, engages in the development and commercialization of the therapies for solid tumors, hematological malignancies, and blood disorders. The company offers Orathecin capsules, a second-generation topoisomerase I inhibitor, which causes single-strand breaks in the DNA of rapidly dividing tumor cells; Dacogen, a pyrimidine analog that decreases the amount of methylation at certain DNA sites; and Nipentis that is used for the treatment of hairy cell leukemia, a type of B-lymphocytic leukemia, as well as shows activity in various autoimmune diseases, including GvHD, bone marrow transplantation and multiple sclerosis. It also offers Mitomycin, Paclitaxel, Mitozytrex, Inhaled Orathecin, Partaject Orathecin, CZ 112, and Cremophor-free paclitaxel for solid tumors; Daunorubicin for Acute leukemias; Surface Safe for surface decontaminate; Partaject busulfan for Neoplastic meningitis/bone marrow transplant; Avicine for Therapeutic Vaccine; and VEGF for anti-angiogenesis. The company sells its products to cancer hospitals, clinics, private practice oncology clinics, oncology distributors, and drug wholesalers in the United States. SuperGen was founded in 1991 and is headquartered in Dublin, California.

Promedior, Inc is a biotechnology company based in South San Francisco, CA, specializing in the development of novel therapeutics for fibrotic diseases. The company focuses on advancing innovative treatments that target the underlying mechanisms of fibrosis to address unmet medical needs in patients. Generated from their business information

AstraZeneca in South San Francisco, CA is a biopharmaceutical company dedicated to pushing the boundaries of science to deliver life-changing medicines. With a focus on corporate transparency, responsible business practices, and community impact, AstraZeneca strives to address some of the biggest healthcare challenges facing humankind. Specializing in oncology, AstraZeneca aims to redefine cancer care for millions of Americans living with cancer by leading a revolution in the field. Through innovative research and a commitment to patient empowerment, AstraZeneca works towards achieving remission, stopping disease progression, and ultimately finding cures for degenerative and life-threatening conditions. Generated from the website